Gyre Therapeutics Inc (GYRE) News

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in...

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a...

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable...

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable...

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia...

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable...

Form 4 - Statement of changes in beneficial ownership of securities

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable...

Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable...

Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage...

Form 8-K - Current report